Raymond James Financial’s CytomX Therapeutics CTMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.27M Sell
467,638
-16,584
-3% -$55.3K ﹤0.01% 3860
2026
Q2
$1.82M Buy
484,222
+104,062
+27% +$397K ﹤0.01% 3556
2026
Q1
$1.79M Buy
380,160
+63,189
+20% +$321K ﹤0.01% 3441
2025
Q4
$1.35M Buy
316,971
+23,411
+8% +$88.9K ﹤0.01% 3582
2025
Q3
$936K Buy
293,560
+10,000
+4% +$22.5K ﹤0.01% 3722
2025
Q2
$644K Buy
+283,560
New +$457K ﹤0.01% 3846

Other funds holding CTMX

Raymond James Financial's CTMX Position: Q3 2026 in Review

Raymond James Financial reduced its CytomX Therapeutics (CTMX) stake by 3.4% in Q3 2026, selling an estimated $55.3K and leaving 467,638 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #3860.

Raymond James Financial first reported a position in CTMX in Q2 2025 and has held it in 6 quarters since. The position peaked at $1.82M in Q2 2026. 194 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

  • Raymond James Financial held 467,638 shares of CytomX Therapeutics worth $1.27M as of Q3 2026.
  • Raymond James Financial sold 16,584 CytomX Therapeutics shares in Q3 2026, an estimated $55.3K.
  • CytomX Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #3860 holding.
  • Raymond James Financial first reported a position in CytomX Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Raymond James Financial's CytomX Therapeutics position peaked at $1.82M in Q2 2026.
  • 194 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.